Business / Finance

RSS
Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration

Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration

Nuclera joins Tech Nation’s Future Fifty program

Nuclera joins Tech Nation’s Future Fifty program

Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies

Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies

Logical Biological recognized as one of ‘Europe's fastest-growing companies’ due to customer centric approach and quality commitment

Logical Biological recognized as one of ‘Europe's fastest-growing companies’ due to customer centric approach and quality commitment

Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

World Vaccine Congress draws leaders from government, science and industry

World Vaccine Congress draws leaders from government, science and industry

Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation

Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation

Metrion Biosciences strengthens team with three key appointments

Metrion Biosciences strengthens team with three key appointments

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution

New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution

INTEGRA supports the next generation of synthetic biologists

INTEGRA supports the next generation of synthetic biologists

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases

PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases

Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production

Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production

Optibrium launches a metabolism prediction software platform tailored to DMPK scientists

Optibrium launches a metabolism prediction software platform tailored to DMPK scientists

Optibrium enables collaborative design in its StarDrop platform

Optibrium enables collaborative design in its StarDrop platform

Developing a novel norovirus vaccine candidate with INTEGRA pipettes

Developing a novel norovirus vaccine candidate with INTEGRA pipettes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.